RxDoctor Payments Data

Vishnu Vardhan Reddy Naravadi, MD

Gastroenterology · Charleston, WVNPI 1760611776

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 30.9% of the total. Reporting peaked in 2019 at $192 and has fallen 83.5% since, to $32 in 2021. That places this record below the midpoint for gastroenterology clinicians in WV, where the typical reported total is $1,371.

$285in general payments, 2019–2025

Across 17 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$88
  • Takeda Pharmaceuticals U.S.A., Inc.$73
  • AbbVie$46
  • Pfizer$29
  • Gilead$20
  • Ferring Pharmaceuticals Inc.$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$285 in reported general payments places this provider in the 20th percentile of 72 gastroenterology providers in West Virginia.

See all gastroenterology providers in West Virginia

Medicare billing

Part B allowed, 2024
$169,488
Medicare patients
585
Services billed
1,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide28$15,215
Sucralfate23$2,607
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates29$2,082
Pantoprazole Sodium107$1,108
Omeprazole62$501
Famotidine13$273
Carvedilol29$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$46$15,21528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 72 gastroenterology providers in West Virginia.

Other gastroenterology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →